Updates

October 01, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Update on ‘Acquisition of Wellness Portfolio of Group Pharmaceuticals Limited’ – Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, We refer to our intimation dated September 23, 2026 wherein we had informed that the Company had signed a Business Transfer Agreement (“BTA”) with Group Pharmaceuticals Limited (“Group Pharma”) for the acquisition of its Wellness Portfolio. Subsequent to fulfilment of the Conditions Precedent under the BTA the transaction has been consummated with effect from today i.e., October 01, 2026. We are also enclosing herewith the Investor Presentation on the acquisition for the information of the Stock Exchanges and investors. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Encl: A/a Jagsonpal Pharmaceuticals Ltd. Acquisition of Wellness portfolio of Group Pharmaceuticals 1st October 2026 Safe Harbor This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and several risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations. These factors include, but not limited to: 1) change in the general market and macro-economic conditions, 2) governmental and regulatory trends, 3) successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 4) movements in currency exchange and interest rates, 5) increase in the competitive pressures and technological developments, 6) changes in the financial conditions of third parties dealing with us, 7) changes in laws and regulations that apply to our customers, suppliers and the pharmaceutical industry. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Jagsonpal Pharmaceuticals Limited may vary materially from those described in the relevant forward-looking statements. The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation because of new information, future events or otherwise. This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. Strategic move strengthens Wellness Portfolio The acquisition of Group Pharmaceuticals’ wellness portfolio is underpinned by our strong and disciplined business model and is a significant step towards our ₹500 Cr ambition. It adds a complementary portfolio, creating opportunities to cross-sell JPL brands through an expanded field force and doctor network thereby enhancing productivity on an overall basis. This is another important step in our journey of last 4 years - each acquisition has added distinct capabilities - Yash Pharma expanded portfolio to Dermatology, Aequitas Healthcare expanded our hospital and institutional reach, and Group Pharmaceuticals adds a consumer wellness pillar to our existing Rx franchise. The current year has been extremely eventful as we have leveraged our strong balance sheet to productive use – share-buyback, enhanced dividends and two value-accretive acquisitions with a focus on building scale, expanding market access and creating long- term value, even as we retain significant optionality with cash reserves in excess of Rs. Manish Gupta 100 crores. Managing Director​​ High Innovation Backed Financial Strength Governance Portfolio fuels Strategic Standards Expansion Agility Initiative towards Disciplined Value Creation The acquisition of Group Pharma’s wellness portfolio adds a complementary Our financial performance is a testament to the strength and growth engine to Jagsonpal. By merging their established brands and field scalability of Jagsonpal. In Q1FY27, revenue grew 9%, operating force with our extensive distribution network, we are instantly unlocking EBITDA surged 21%, and PAT expanded 22%, demonstrating powerful untapped markets, driving higher volumes, and accelerating brand operating leverage. productivity. This robust momentum has empowered the strategic acquisition of Our M&A playbook is proven and precise: acquire strategically, integrate Group Pharma Portfolio. Consistent with our judicious and disciplined seamlessly, and scale aggressively. We are not buying businesses; but their approach to cash management, we have engineered a highly derisked value to our business. Yash Pharma business is fully integrated and transaction structure. By structuring almost 50% of the consideration delivering. Aequitas is unlocking corporate hospital channel, while Group as deferred payments, we have preserved our liquidity and aligned the Pharma is the next catalyst in this winning blueprint. acquisition's success with future performance—allowing us to invest behind growth while rigorously maintaining balance-sheet discipline. Our core business remains our unshakeable foundation. Our mandate is clear: replicate this execution excellence across acquired platform. We are Backed by strong cash generation and a lean working-capital model, engineering a diversified, high-performance powerhouse built for we continue to create Shareholders wealth by Investing prudently in sustainable, compounding shareholder value. organic as well as inorganic opportunities. Wellness portfolio of Group Pharmaceuticals Strengthening the presence with a complementary Rx- brand portfolio Wellness Portfolio of Strategic Acquisition for profitable growth ~ ₹23.7 Cr ~ ₹23.0 Cr ~ ₹24.6 Cr 6 2 Key Brands Maximum Additional Upfront FY26 States consideration (6 SKUs) Consideration Revenue Presence linked to FY28 sales K E Y R A T I O N A L E Expands Strengthens Creates a larger Rx- brand market presence platform for Margin accretive portfolio and Dr reach future growth About the Business Established Wellness Rx Portfolio with strong regional presence Company Snapshot Financial Performance (Wellness Portfolio) –INR Crs 30 78.4% 26.3 46 Years Old Wellness Portfolio ~2 Key Brands 24.6 Established pharmaceutical business Rx – Branded generics portfolio ~6 SKUs across the portfolio 78.1% 20 78.0% 77.8% 15 12.5 77.7% ~ ₹24.6 Cr ~30,000 Drs 10 ~ 150 Total Employees FY26 Net Revenue Established GP & specialist 5 coverage across 6 states 0 77.0% FY25 FY26 H1 FY27E 6 States 300+ Stockist UP | Rajasthan | Karnataka | Revenue Gross Margin Maharashtra | MPCG| Goa Key Brands (FY26); Source: Pharmarack MAT July 2026 Geographic Footprint Top 3 markets UP MPCG 29% Rajasthan Hemozink ® (Hematinic) Sudin ®(Respiratory) Karnataka UP 20% Maharashtra Karnataka 18% ~₹15.5 Cr ~₹20.1 Cr MPCG (As of FY26 revenue) Value Creation: Expanded Reach, Strong Synergies A complementary portfolio that creates a larger scalable Rx pla [Showing first 8,000 characters — download PDF for full document]